Xeris Biopharma (XERS) Stock Price, News & Analysis

Company Overview

Xeris Biopharma, Inc. is a specialty pharmaceutical company focused on developing and commercializing therapies for patients with endocrinology, gastroenterology, and related rare or chronic conditions. The company uses proprietary formulation technologies designed to deliver medicines that are difficult to formulate or administer through conventional methods, including its XeriSol and XeriJect platforms.

Xeris’ commercial portfolio includes Gvoke, a ready-to-use glucagon injection used to treat severe hypoglycemia; Keveyis (dichlorphenamide), a treatment for primary periodic paralysis; and Recorlev (levoketoconazole), an oral therapy for endogenous hypercortisolemia associated with Cushing’s syndrome. The company also markets Ogluo, a glucagon autoinjector, in certain markets. Its products are primarily marketed in the United States, with selected international availability supported through commercial partners and regional arrangements.

The company was established as Xeris Pharmaceuticals and became a publicly traded company in 2018. In 2021, Xeris completed a combination with Strongbridge Biopharma, expanding its portfolio and adding therapies focused on rare endocrine diseases. In addition to its commercial products, Xeris continues to develop medicines and drug-delivery applications based on its proprietary formulation platforms.

Key Stats

• Today's Range: $9.04 to $9.34
• 50-Day Range: $7.36 to $9.98
• 52-Week Range: $5.25 to $11.33
• Volume: 1.38 million shs
• Average Volume: 3.14 million shs
• Market Capitalization: $1.66 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $12.80
• Consensus Rating: Hold

Xeris Biopharma Stock Analysis - MarketRank™

Xeris Biopharma scored higher than 72% of companies evaluated by MarketBeat, and ranked 169th out of 887 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.8 / 5
• Analyst Rating: Hold

Consensus Rating

Xeris Biopharma has received a consensus rating of Hold. The company's average rating score is 2.43, and is based on no strong buy ratings, 4 buy ratings, 2 hold ratings, and 1 sell rating.

Upside Potential

Xeris Biopharma has a consensus price target of $12.80, representing about 41.0% upside from its current price of $9.08.

Amount of Analyst Coverage

Xeris Biopharma has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 328.57%

Earnings Growth

Earnings for Xeris Biopharma are expected to grow by 328.57% in the coming year, from $0.07 to $0.30 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Xeris Biopharma is -82.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Xeris Biopharma is -82.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Xeris Biopharma has a P/B Ratio of 113.50. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

4.62% of the float of Xeris Biopharma has been sold short.

Short Interest Ratio / Days to Cover

Xeris Biopharma has a short interest ratio ("days to cover") of 4.83.

Change versus previous month

Short interest in Xeris Biopharma has recently increased by 0.22%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Xeris Biopharma does not currently pay a dividend.

Dividend Growth

Xeris Biopharma does not have a long track record of dividend growth.

News and Social Media

• Score: 2.8 / 5
• News Sentiment: 0.46

News Sentiment

Xeris Biopharma has a news sentiment score of 0.46. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 21 news articles for Xeris Biopharma this week, compared to 4 articles on an average week.

Search Interest

Only 3 people have searched for XERS on MarketBeat in the last 30 days. This is a decrease of -63% compared to the previous 30 days.

MarketBeat Follows

5 people have added Xeris Biopharma to their MarketBeat watchlist in the last 30 days. This is an increase of 400% compared to the previous 30 days.

Company Ownership

• Score: 1.4 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Xeris Biopharma insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,585,718.00 in company stock.

Percentage Held by Insiders

4.35% of the stock of Xeris Biopharma is held by insiders.

Percentage Held by Institutions

42.75% of the stock of Xeris Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/06/2026
• Today: 10/04/2026
• Next Earnings (Estimated): 11/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:XERS
• CIK: 1867096
• Web: www.xerispharma.com
• Phone: (844) 445-5704
• Fax: N/A
• Employees: 435
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Xeris Biopharma: $12.80
• High Price Target: $18.00
• Low Price Target: $8.00
• Potential Upside/Downside: +41.0%
• Consensus Rating: Hold
• Rating Score (0-4): 2.43
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.11)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 129.71
• P/E Growth: N/A
• Net Income: $550 thousand
• Net Margins: -5.12%
• Pretax Margin: -5.12%
• Return on Equity: 338.21%
• Return on Assets: 3.50%

Debt

• Debt-to-Equity Ratio: 17.00
• Current Ratio: 1.45
• Quick Ratio: 1.02

Sales & Book Value

• Annual Sales: $291.85 million
• Price / Sales: 5.67
• Cash Flow: $0.10 per share
• Price / Cash Flow: 90.65
• Book Value: $0.08 per share
• Price / Book: 113.50

Miscellaneous

• Outstanding Shares: 182,320,000
• Free Float: 174,389,000
• Market Cap: $1.66 billion
• Optionable: Optionable
• Beta: 0.53